Zhang YJ, Yin L, Li J. Protective effect of recombinant human brain natriuretic peptide against contrast-induced nephropathy in elderly acute myocardial infarction patients: A randomized controlled trial. World J Clin Cases 2022; 10(33): 12221-12229 [PMID: 36483837 DOI: 10.12998/wjcc.v10.i33.12221]
Corresponding Author of This Article
Jun Li, BSc, Chief Nurse, Department of Imaging, 904th Hospital of Joint Logistic Support Force of PLA, No. 101 Xing Yuan North Road, Wuxi 214044, Jiangsu Province, China. sm2008@21cn.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Randomized Controlled Trial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Zhang YJ, Yin L, Li J. Protective effect of recombinant human brain natriuretic peptide against contrast-induced nephropathy in elderly acute myocardial infarction patients: A randomized controlled trial. World J Clin Cases 2022; 10(33): 12221-12229 [PMID: 36483837 DOI: 10.12998/wjcc.v10.i33.12221]
World J Clin Cases. Nov 26, 2022; 10(33): 12221-12229 Published online Nov 26, 2022. doi: 10.12998/wjcc.v10.i33.12221
Protective effect of recombinant human brain natriuretic peptide against contrast-induced nephropathy in elderly acute myocardial infarction patients: A randomized controlled trial
Yi-Jing Zhang, Lin Yin, Jun Li
Yi-Jing Zhang, Lin Yin, Jun Li, Department of Imaging, 904th Hospital of Joint Logistic Support Force of PLA, Wuxi 214044, Jiangsu Province, China
Author contributions: Zhang YJ and Li J contributed equally to this work; Zhang YJ, Yin L, and Li J gave the conception and designed the research study; Zhang YJ performed the research; Zhang YJ, Yin L, and Li J analyzed the data; Zhang YJ, Yin L, and Li J wrote the manuscript; all authors gave their final approval and agree to be accountable for all aspects of the work.
Institutional review board statement: The study protocol was approved by the Anhui Medical University Affiliated Wuxi Clinical College Clinical Research Ethics Committee (Approval No. 2016-YXLL-051).
Clinical trial registration statement: This study was registered at Hospital Clinical Trial Registry (No. WXCTR-IM-171162).
Informed consent statement: Written informed consent was obtained from the patients whose competence was established by their accurate orientation for time, place, and person, as well as an understanding of the recruiter’s description of the trial or from their next of kin or legal representative.
Conflict-of-interest statement: The authors declare that there are no conflicting interests to disclose.
Data sharing statement: The corresponding author may provide the datasets used in the study upon request.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Corresponding author: Jun Li, BSc, Chief Nurse, Department of Imaging, 904th Hospital of Joint Logistic Support Force of PLA, No. 101 Xing Yuan North Road, Wuxi 214044, Jiangsu Province, China. sm2008@21cn.com
Received: July 17, 2022 Peer-review started: July 17, 2022 First decision: September 9, 2022 Revised: September 21, 2022 Accepted: October 31, 2022 Article in press: October 31, 2022 Published online: November 26, 2022 Processing time: 129 Days and 2.4 Hours
Core Tip
Core Tip: Increasing evidence indicates that emergency percutaneous coronary intervention (PCI) is the most effective method for the treatment of acute myocardial infarction (AMI). However, with the increase of emergency PCI, contrast-induced nephropathy (CIN) is becoming more and more common, which also leads to the increase of the proportion of patients with renal dysfunction, aggravating the cost of hospitalization and prolonging the length of hospital stay. CIN cannot be managed or prevented with current medications. Recombinant human B-type natriuretic peptide (rhBNP) is the natriuretic peptide receptor A, and increasing reports have demonstrated that rhBNP can improve AMI and heart failure. However, whether it can improve renal function and decrease the risk of CIN in elderly patients is still unclear. In this study, we explored the effectiveness of rhBNP treatment in postoperative CIN in elderly AMI patients. We found that early application of rhBNP after primary PCI could protect renal function, reduce serum creatinine and cystatin C levels, improve creatinine clearance rate, and decrease the risk of CIN and acute heart failure in AMI patients. We showed rhBNP as an effective drug to prevent CIN in the elderly after PCI.
